GeneDx Holdings (NASDAQ: WGS) reported Q2 EPS of ($0.28), $0.14 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $111.01 million.

GUIDANCE:

GeneDx Holdings sees Q3 2026 revenue of $122-124 million, versus the consensus of $126 million.

GeneDx Holdings sees FY2026 revenue of $475-490 million, versus the consensus of $478.4 million.

For earnings history and earnings-related data on GeneDx Holdings (WGS) click here.